(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.27%) $79.16
(-0.05%) $2.03
(0.17%) $2 313.50
(0.36%) $26.93
(-0.01%) $962.50
(-0.05%) $0.932
(-0.09%) $10.98
(-0.05%) $0.797
(-2.30%) $91.11
Quarter results today
(bmo 2024-05-02)
Expected move: +/- 12.80%
@ $10.44
Išleistas: 13 vas. 2024 @ 17:07
Grąža: 58.10%
Ankstesnis signalas: vas. 12 - 20:04
Ankstesnis signalas:
Grąža: -6.09 %
Live Chart Being Loaded With Signals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States...
Stats | |
---|---|
Šios dienos apimtis | 15 387.00 |
Vidutinė apimtis | 29 803.00 |
Rinkos kapitalizacija | 97.31M |
EPS | $0 ( 2024-02-08 ) |
Kita pelno data | ( $-1.940 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.840 |
ATR14 | $0.196 (1.17%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-05-01 | Zung Jonathan B. | Buy | 500 000 | Employee stock option (right to buy) |
2023-05-01 | Zung Jonathan B. | Buy | 0 | |
2023-01-23 | Kaitin Kenneth I | Buy | 85 000 | Non Qualified Stock Option |
2023-01-23 | Hohneker John | Buy | 85 000 | Non Qualified Stock Option |
2023-01-23 | Rubin Marc | Buy | 85 000 | Non Qualified Stock Option |
INSIDER POWER |
---|
86.33 |
Last 97 transactions |
Buy: 14 857 117 | Sell: 1 304 959 |
Curis Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
BUR | 0.887 |
ARCT | 0.884 |
PSTV | 0.882 |
IFRX | 0.882 |
EZFL | 0.878 |
VTSI | 0.866 |
SBET | 0.864 |
MDRR | 0.861 |
FRSX | 0.86 |
LGMK | 0.859 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
AMRB | -0.912 |
PKOH | -0.886 |
SMH | -0.881 |
SNCY | -0.873 |
GPRE | -0.85 |
VOXX | -0.846 |
VTRU | -0.833 |
PSCC | -0.831 |
PSEC | -0.828 |
HLNE | -0.828 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Curis Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $10.02M |
Bruto pelnas: | $9.81M (97.88 %) |
EPS: | $-8.96 |
FY | 2023 |
Pajamos: | $10.02M |
Bruto pelnas: | $9.81M (97.88 %) |
EPS: | $-8.96 |
FY | 2022 |
Pajamos: | $10.16M |
Bruto pelnas: | $9.91M (97.47 %) |
EPS: | $-12.92 |
FY | 2021 |
Pajamos: | $10.65M |
Bruto pelnas: | $10.12M (94.99 %) |
EPS: | $-0.500 |
Financial Reports:
No articles found.
Curis Inc
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.